RBC Capital maintained its Outperform rating and $283.00 price target on Humana stock (NYSE: HUM ) following the company's 2025 Investor Conference. The decision reflects RBC's confidence in Humana's long-term earnings growth strategy despite near-term challenges. According to InvestingPro data, Humana, currently trading at $243.08 with a market cap of $29.35B, appears undervalued based on its Fair Value analysis. RBC noted that Humana is prioritizing long-term earnings growth over immediate margin recovery as the company navigates through Stars rating headwinds. While Humana did not provide specific guidance, RBC believes management comments suggest 2028 earnings per share could reach approximately $38-42, including Stars bonus payments. The company's solid financial foundation is evident in its 10.09% revenue growth and healthy P/E ratio of 17.19.